Plaque volume rose by 53 % in
women on the placebo, while it declined by 4.6 % in those taking garlic.
So, while
the women on placebo had lower quit rates than men, the women taking naltrexone had quit rates similar to men.
At the end of treatment, the women who received the drug reported a 21 - point reduction on a standard scale of depression symptoms, compared with about 9 points for
the women on a placebo.
But 2 years ago, the Women's Health Initiative reported that older women taking hormone supplements had more, not fewer, heart problems than
women on placebo.
Not exact matches
Randomized, double blind
placebo - controlled trial: Effects of myo - inositol
on ovarian function and metabolic factors in
women with PCOS.
There was also less than one additional case for every 1,000
women per year for heart disease and for stroke in the hormone - treated
women compared with those
on placebo.
For example, in the combined hormone therapy trial, treated 50 - to 59 - year - olds had five additional cases of heart disease and five more strokes per 10,000
women annually compared with the same - aged group
on placebo.
Women who were given testosterone but thought it was a
placebo,
on the other hand, offered fair - share splits 60 percent of the time — significantly more often than those who correctly guessed they got testosterone (30 percent) or a
placebo (50 percent).
Karen E. Hansen, M.D., M.S., of the University of Wisconsin School of Medicine and Public Health, Madison, and colleagues compared the effects of
placebo, low - dose cholecalciferol (a form of vitamin D) and high - dose cholecalciferol
on one - year changes
on total TFCA, bone mineral density, sit - to - stand tests and muscle mass in 230 postmenopausal
women (75 or younger) with vitamin D insufficiency.
The trial found that
on a 13 - point scale,
women who took the drug sold as Diclectin in Canada (Diclegis in the United States) reported symptom reductions that were 0.7 points greater than
women who took a
placebo.
In this study, five
women between the ages of 18 and 40 suffering from HA were given 8 - hour intravenous infusions of either kisspeptin or a saline
placebo on six different occasions.
But a trial in which Kenyan
women received a tenofovir pill daily was halted earlier this year after recipients seemed to be no better protected than those
on placebos.
The study tracked 2,947
women, ages 65 to 79, over five years and found that 28 of the
women on estrogen developed dementia, compared with only 19 of those
on placebos.
Half of the postmenopausal
women had been
on estradiol, a type of estrogen therapy, for approximately five years, while the others had received a
placebo.
Half of the
women were given a daily pill of letrozole for an additional 5 years, while the rest were put
on a
placebo.
The researchers found that
women who took olaparib had a median of 8.4 months before their cancer came back, compared to 4.8 months for those
on the
placebo.
In
women during postpartum days 3 - 5 (after giving birth to preterm infants), supplementation of 250 mg moringa oleifera leaf extract twice daily appears to increase milk production in a time dependent manner
on the first day of supplementation (31 % increase over
placebo) as well as the second (48 %) and third (165 %) day.
On the other hand, «twice as many
women given the
placebo reported lower satisfaction with their pain relief compared to those provided the [epidural] anesthetic,» Hess said.
These terms tell us little to nothing about what's actually going
on in a
woman's body, yet the gold standard of treatment is medications that may only be riding a
placebo effect, and may put that
woman — and even her family — at risk, all while neglecting to investigate underlying drivers.
While the International Journal of Biomedical Science study found that it was «reasonable» to describe maca as having beneficial effects and allowing for a «substantial reduction of menopausal discomfort»
on a small sample of early - postmenopausal
women, the study also stated there was a definite
placebo effect, so «further, more complex» research was needed.
Of which 15
women were in the treatment group with a food supplement based
on marine polysacchardies derived from fish and a natural mix of antioxidants for 2 months and the other 15 with a
placebo.
The impact of metformin, oral contraceptives and lifestyle modification,
on polycystic ovary syndrome in obese adolescent
women in two randowmized,
placebo - controlled clinical trials.
Randomized, double blind
placebo - controlled trial: effects of myo - inositol
on ovarian function and metabolic factors in
women with PCOS.Europ rev med pharm sci.
The effects of coenzyme Q10 supplementation
on glucose metabolism and lipid profiles in
women with polycystic ovary syndrome: a randomized, double - blind,
placebo - controlled trial.
Randomized, double blind
placebo - controlled trial: effects of myo - inositol
on ovarian function and metabolic factors in
women with PCOS.
Methods: A double - blind,
placebo - controlled study was initiated to determine the effects of FertilityBlend for
Women, a proprietary nutritional supplement containing chasteberry, green tea, L - arginine, vitamins (including folate) and minerals,
on progesterone level, basal body temperature, menstrual cycle length, pregnancy rate and side - effects.
The only reason why a
woman seems to have a «normal» cycle while
on the pill is because the
placebo pills taken during days 21 - 28 creates a «withdrawal bleed.»
The
women on the fiber - supplemented diets lost 8.0 kg versus 5.8 kg for the
placebo group (p < 0.05).
Among the
women who did report breast tenderness at the beginning, the risk at one - year was about 1.26 times that of their counterparts
on placebos.